Sun, Sep 21, 2014, 7:58 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou Mar 5, 2013 5:43 PM Flag

    Whip's $150/share target starting to make sense

    EGFRvIII expression was detected in 42% of HNSCC tumors where EGFRvIII was always found in conjunction with wild-type EGFR. HNSCC cells expressing EGFRvIII showed increased proliferation in vitro and increased tumor volumes in vivo compared with vector-transfected controls. Furthermore, EGFRvIII-transfected HNSCC cells showed decreased apoptosis in response to cisplatin and decreased growth inhibition following treatment with C225 compared with vector-transfected control cells. CONCLUSIONS: EGFRvIII is expressed in HNSCC where it contributes to enhanced growth and resistance to targeting wild-type EGFR. The antitumor efficacy of EGFR targeting strategies may be enhanced by the addition of EGFRvIII-specific blockade.

    EGF receptor variant III (EGFRvIII) is the most common variant of the EGF receptor observed in human tumors. It results from the in frame deletion of exons 2-7 and the generation of a novel glycine residue at the junction of exons 1 and 8. This novel juxtaposition of amino acids within the extra-cellular domain of the EGF receptor creates a tumor specific and immunogenic epitope. EGFRvIII expression has been seen in many tumor types including glioblastoma multiforme (GBM), breast adenocarcinoma, non-small cell lung carcinoma, ovarian adenocarcinoma and prostate cancer, but has been rarely observed in normal tissue. Because this variant is tumor specific and highly immunogenic, it can be used for both a diagnostic marker as well as a target for immunotherapy. Unfortunately many of the monoclonal and polyclonal antibodies directed against EGFRvIII have cross reactivity to wild type EGFR or other non-specific proteins. Furthermore, a monoclonal antibody to EGFRvIII is not readily available to the scientific community.

    Rindopepimut (CDX-110) - Vaccine for EGFRvIII-expressing tumors. Pfizer was silly to walk away from this blockbuster.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Least we not forget this post. Celldex is rare biotech. 9+ potential blockbusters and they are fully owned. I hope Celldex presents at Roth.

      Sentiment: Strong Buy

    • This stock has a lot to offer. cdx-110 and cdx-011 should get approved before the other drugs in their pipeline.

      Sentiment: Strong Buy

    • Weightbayou,

      Do you have a link to that article?

      Bladerunner

      • 2 Replies to bladerunner1718
      • Blade, notice that Celldex refers to the CDX-110 vaccine as one for EGFRvIII-expressing tumors, not just a vaccine for GBM.

        Rindopepimut (CDX-110) - Vaccine for EGFRvIII-expressing tumors: Our lead clinical development program, rindopepimut, is an immunotherapy that targets the tumor specific oncogene called EGFRvIII, a functional and permanently activated mutation of the epidermal growth factor receptor (EGFR), a protein that has been well validated as a target for cancer therapy. Unlike EGFR, EGFRvIII has not been detected at a significant level in normal tissues, but has been identified in multiple cancer types; therefore, targeting of this tumor-specific molecule is not likely to impact healthy tissues, EGFRvIII can turn normal cells into malignant cells through its well documented oncogenic properties, providing a constant growth signal to tumor cells which express it. Consequently, cells producing EGFRvIII have an enhanced capacity for unregulated growth. Rindopepimut is designed to activate the patient’s own immune system against tumor cells expressing the EGFRvIII mutation.

        Sentiment: Strong Buy

      • Off hand I don't. I think one was from a clinical cancer journal. I don't think Yahoo would allow me to post links anyway. I forgot to mention the info is from 2 separate articles. The point I am trying to get across is that the cdx-110 vaccine could have other indications besides brain cancer. Even on the Celldex website it mentions its potential. To be honest, Celldex has so many things going on I can't keep up.

        Sentiment: Strong Buy

    • weight take alook at Cris again that is what I was speaking of about their pipeline but I have not gotten into the nuts and bolts of it yet the EGFR factor. That and the HDAC factor I believe will make CRIS worth investing the rolalty on the current products so reminds me of what MEDX did. These guys here understand what happen at MEDX and know better. I would never not say a 150 price target is not possible with all these disease marker agents and having effect in brain, renal, breast and etc,,,

    • I'm pleased you remember that statement of mine. I stand by it. Celldex Therapeutics is emerging from gestation and will soon be recognized as a prodigy. You want to invest in prodigies before too many other people realize their potential.

      Sentiment: Strong Buy

      • 1 Reply to whippersnapper65
      • I believe Celldex could become a leader in combo therapies.

        "CDX-1401 represents a new generation of off-the-shelf dendritic cell targeted vaccines built upon excellent preclinical activity data," said Tom Davis, M.D., Chief Medical Officer of Celldex Therapeutics. "The initial data from this ongoing study confirm safety and immunogenicity even in patients with advanced cancer who have received multiple prior therapies. CDX-1401 has passed the initial Phase 1 hurdles and we look forward to forthcoming cohorts that will include additional TLR agonists in combination regimens."

        Sentiment: Strong Buy

    • Go CLDX! How is everyone doing?

 
CLDX
14.05-0.04(-0.28%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.